Adlai Nortye (ANL) Non-Current Deffered Revenue (2023 - 2025)
Adlai Nortye's (ANL) quarterly Non-Current Deffered Revenue came in at $5.0 million in Q2 2025, little changed on a QoQ basis from $5.0 million in Q4 2024.
Adlai Nortye (ANL) Non-Current Deffered Revenue (2023 - 2025) Analysis & Trends
Adlai Nortye (ANL) has 3 years of Non-Current Deffered Revenue data on file, last reported at $5.0 million in Q2 2025.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $5.0 million in Q2 2025; TTM through Jun 2025 was $5.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $5.0 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue for Q2 2025 stood at $5.0 million, roughly flat from $5.0 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for ANL reached as high as $5.0 million in Q4 2023 and fell as low as $5.0 million in Q4 2023.
- Historically, Non-Current Deffered Revenue has averaged $5.0 million across 3 years, with a median of $5.0 million in 2023.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2024 and fell as far as 0.0% in 2024.
- Year by year, Non-Current Deffered Revenue stood at $5.0 million in 2023, then changed by 0.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $5.0 million in Q2 2025, $5.0 million in Q4 2024, and $5.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Adlai Nortye | 1.16 Bn | 1.15 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 5.00 Mn |